Has Emilio Poggio, MD received payments from drug or device companies?

Yes. Drug and device makers reported $41,311 in general payments to Emilio Poggio, MD across 55 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Emilio Poggio, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Emilio Poggio, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Emilio Poggio, MD

Nephrology · Cleveland, OHNPI 1700976891

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 41.9% of the total. Reporting peaked in 2022 at $13,768 and has fallen 63.7% since, to $4,996 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,311in general payments, 2019–2025

Across 55 payments — averaging $751.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$17K
Veloxis Pharmaceuticals, Inc.$9K
Amgen$9K
Apellis Pharmaceuticals, Inc.$3K
Argenx US, Inc.$600
Novartis$570
plus $918 from 5 others

$13,692in research payments, 2019–2025

Across 1 payment — averaging $13,692 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

One Lambda, Inc.$14K

What the payments were for

Consulting fees$16,57340%
Speaking & faculty fees$18,68545%
Travel & lodging$4,02310%
Food & beverage$1,9955%
Education$360%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	9	$17,322
Veloxis Pharmaceuticals, Inc.	8	$9,418
Amgen(2 entities)	9	$9,393
Apellis Pharmaceuticals, Inc.	2	$3,091
Argenx US, Inc.	1	$600
Novartis	14	$570
AstraZeneca(2 entities)	5	$432
Sanofi	1	$136
Mallinckrodt Enterprises LLC	4	$135
Otsuka America Pharmaceutical, Inc.	1	$121
E.r. Squibb & Sons, L.L.C.	1	$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

THYMOGLOBULIN$13,488
Envarsus$9,357
UPLIZNA$6,300
Empaveli$3,068
KRYSTEXXA$2,944
VYVGART HYTRULO$600
LOKELMA$342
Vanrafia$205
Fabhalta$205
ACTHAR$122
JYNARQUE$121

How this compares

$41,311 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio →

Medicare billing

Part B allowed, 2024

$35,950

Medicare patients

160

Services billed

342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tacrolimus	19	$9,378
Valganciclovir Hcl	26	$6,199
Cinacalcet Hcl	13	$2,263
Mycophenolate Mofetil	22	$1,620
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	163	$1,493
Prednisone	193	$1,091
Tamsulosin Hcl	26	$248
Metoprolol Succinate	16	$213
Carvedilol	41	$203
Furosemide	20	$87
Amlodipine Besylate	45	$59
Losartan Potassium	11	$55
Atorvastatin Calcium	20	$54
Metoprolol Tartrate	13	$32

Paid to pharmacies, not to this prescriber.

Other nephrology in Cleveland

Georges NakhoulCleveland$255K
Sankar NavaneethanCleveland$253K
Sevag DemirjianCleveland$158K
Elias BassilCleveland$80K
Ali MehdiCleveland$76K
Amitkumar PatelCleveland$70K
Corey CavanaughCleveland$35K
James SimonCleveland$29K
Ziad ZakyCleveland$20K
Nishigandha PradhanCleveland$17K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →